Advertisement

Topics

Comparison of Two Commercial Preparations of Botulinum Toxin Type A

2014-08-27 03:20:01 | BioPortfolio

Summary

The objective of this study is to compare the action halos of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as more detailed data on the effectiveness in reduction of wrinkles and duration of action on the upper part of the face of both products, trough scales and photographs evaluations.

Description

This was a monocentric, prospective, randomized and double-blind study. Fifty nine female patients, presenting with moderate to severe forehead wrinkles, with sweating ability who had never undergone previous BoNT-A injections were enrolled. There were two randomizations, one related to the dose-equivalence (2:1U and 2.5:1U), both reconstituted in the same volume of 0.02 mL per point and another related to the forehead side (left or right) for application of the tested drugs. Baseline, twenty-eight and 112 days later, clinical and photographic assessments, Minor´s test, and electromyographic (EMG) evaluations were performed.

Study Design

Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Wrinkles in Frontal Area

Intervention

BOTULINUM TOXIN TYPE-A

Location

Brazilian Center for Dermatological Studies
Porto Alegre
Rio Grande do Sul
Brazil
90570-040

Status

Completed

Source

Brazilan Center for Studies in Dermatology

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:20:01-0400

Clinical Trials [781 Associated Clinical Trials listed on BioPortfolio]

Field of Effects of Two Commercial Preparations of Botulinum Toxin Type A

The objective of this study is to compare the field of effects of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as mo...

NT 201 in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

NT 201 is a Botulinum toxin type A preparation free of complexing proteins. Injected into the muscle, NT 201 causes a reversible local relexation of the injected muscle. Botulinum toxin ty...

Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia

The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.

Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia

The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck

PubMed Articles [12523 Associated PubMed Articles listed on BioPortfolio]

An objective method to assess the improvements of skin texture roughness after botulinum toxin type a treatment of crow's feet.

Photo-numeric scales could lack precision and objectivity on evaluating the improvements on wrinkles after a treatment with botulinum toxin type A. The authors suggest a new digital evaluation method ...

Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.

To determine the effects of botulinum toxin type A (BTX-A) injection on dry eye signs, symptoms, and tear cytokine levels in patients with intractable dry eye disease (DED).

Use of botulinum toxin in Parkinson's disease.

Botulinum toxin has emerged as an important therapeutic intervention within the realm of movement disorders, especially for focal and generalized dystonias. Botulinum toxin has additionally been used ...

Efficacy and Safety of Botulinum Toxin Type A in Spasticity Caused by Spinal Cord Injury: A Randomized, Controlled Trial.

BACKGROUND Baclofen is approved by the US FDA to treat spasticity, but its sustained use may cause drug addiction. The objective of this study was to compare the efficacy and safety of botulinum toxin...

Six-Month Comparative Analysis Monitoring the Progression of the Largest Diameter of the Sweating Inhibition Halo of Different Botulinum Toxins Type-A.

Excessive sweating is a clinical condition that can be improved with type-A botulinum toxin (BTX-A).

Medical and Biotech [MESH] Definitions

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type G. Though it has been isolated from soil, no outbreaks involving this type have been recognized.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type C which is neurotoxic to ANIMALS, especially CATTLE, but not humans. It causes dissociation of ACTIN FILAMENTS.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type D which is neurotoxic to ANIMALS, especially CATTLE, but not humans.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type E which is neurotoxic to humans and animals.

Subtype of CLOSTRIDIUM BOTULINUM that produces botulinum toxin type F which is neurotoxic to humans and animals.

More From BioPortfolio on "Comparison of Two Commercial Preparations of Botulinum Toxin Type A"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial